IP Library Patent Application 12951620
Patent Application
App. No. 12/951,620

HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/951,620
Abstract

A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.

Claims (9)

1 . A pharmaceutical composition comprising ethyl eicosapentaenoic acid, wherein the pharmaceutical composition contains less than about 5%, in aggregate, of any fatty acid that competes with eicosapentaenoic acid for binding to a biological site of action.

2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition contains less than 5% of any single fatty acid that competes with eicosapentaenoic acid for binding to a biological site of action.

3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition contains less than 3% of any single fatty acid that competes with eicosapentaenoic acid for binding to a biological site of action.

4 . The method of claim 1 wherein the relevant site of action comprises phosphlipids, an enzyme, or a membrane.

5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition contains less than 5%, in aggregate, of docosahexaenoic acid, docosapentaenoic acid, arachidonic acid, and derivatives thereof.

6 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition contains less than 3% of each of docosahexaenoic acid, docosapentaenoic acid, arachidonic acid, and derivatives thereof.

7 . The pharmaceutical composition of claim 1 , wherein the ethyl eicosapentaenoic acid is present in an amount of 250 mg to 1000 mg.

8 . The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is present in capsule, emulsion, solution, dispersion, suppository, pessary, powder microcapsule, tablet, topical patch, or intravenous solution form.

9 . The pharmaceutical composition of claim 4 , wherein the enzyme is selected from the group consisting of: a phospholipase, a phospholipase A 2 , PLC, coenzyme A, a fatty acid coenzyme A ligase, FACL-4, an acyl-CoA synthetase, an acyl-CoA:lysophopholipid acytransferase, an acyltransferase, caspase I, and interleukin converting enzyme (ICE).

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: CPPIB CREDIT EUROPE S.À R.L.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 054484/0552 →
SECURITY INTEREST Recorded Dec 21, 2017
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044938/0257 →
PATENT SECURITY ASSIGNMENT AND ASSUMPTION AGREEMENT Recorded Dec 20, 2017
From: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044956/0395 →
SECURITY AGREEMENT Recorded Dec 19, 2012
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
Reel/Frame 029499/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2012
From: AMARIN CORPORATION PLC
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 028295/0289 →
PROOF OF OWNERSHIP OF SHARES Recorded May 25, 2012
From: AMARIN NEUROSCIENCE LIMITED
To: AMARIN CORPORATION PLC
Reel/Frame 028275/0333 →
CHANGE OF NAME Recorded May 25, 2012
From: LAXDALE LIMITED
To: AMARIN NEUROSCIENCE LIMITED
Reel/Frame 028275/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2012
From: PEET, MALCOLM; VADDADI, KRISHNA S.
To: LAXDALE LIMITED
Reel/Frame 028270/0071 →